{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:08:43Z","timestamp":1784862523234,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lymph-node (LN) metastasis in prostate cancer (PC) is a main risk factor for tumor recurrence after radical prostatectomy (RP). Molecular analysis facilitates detection of small-volume LN metastases with higher sensitivity than histopathology. We aimed to prospectively evaluate six candidate gene markers for detection of pelvic LN metastases and to determine their ability to predict biochemical recurrence-free survival (bRFS) in patients treated with RP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The expression of kallikrein 2, 3, and 4 (KLK2, KLK3, and KLK4), prostate-specific membrane antigen (PSMA), transmembrane serine protease 2 (TMPRSS2) and transient receptor potential cation channel subfamily M member 8 (TRPM8) was assessed using qPCR. We analyzed LNs from 111 patients (intermediate PC, <jats:italic>n<\/jats:italic>\u2009=\u200932 (29%); high-risk PC, <jats:italic>n<\/jats:italic>\u2009=\u200979 (71%)) who underwent RP and extended pelvic lymph-node dissection without neoadjuvant treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 2411 LNs were examined by molecular and histopathologic examination. Histopathology detected 69 LN metastases in 28 (25%) patients. KLK2 and KLK3 diagnostically performed best and classified all pN1-patients correctly as molecular node-positive (molN1\/pN1). The concordance on LN level was best for KLK3 (96%). KLK2, KLK3, KLK4, PSMA, TMPRSS2, and TRPM8 reclassified 27 (24%), 32 (29%), 29 (26%), 8 (7%), 13 (12%), and 23 (21%) pN0-patients, respectively, as node-positive (pN0\/molN1). On multivariable cox regression analysis molecular LN status (molN1 vs. molN0) using KLK3 (HR 4.0, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) and TMPRSS2 (HR 5.1, <jats:italic>p<\/jats:italic>\u2009=\u20090.02) were independent predictors of bRFS. Median bRFS was shorter in patients with only molecular positive LNs (molN1\/pN0) for KLK3 (24 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and for TMPRSS2 (12 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) compared to patients with negative nodes (molN0\/pN0) (median bRFS not reached).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For diagnostic purposes, KLK3 showed highest concordance with histopathology for detection of LN metastases in PC patients undergoing RP. For prognostic purposes, KLK3 and TMPRSS2 expression were superior to histopathologic LN status and other transcripts tested for molecular LN status. We suggest a combined KLK3\/TMPRSS2 panel as a valuable diagnostic and prognostic tool for molecular LN analysis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41391-020-00283-3","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T16:03:09Z","timestamp":1601049789000},"page":"362-369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy"],"prefix":"10.1038","volume":"24","author":[{"given":"Lukas","family":"Lunger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Retz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Bandur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Souchay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Vitzthum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Weirich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Autenrieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Thalgott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Herkommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florestan","family":"Koll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-0628","authenticated-orcid":false,"given":"Matthias M.","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"283_CR1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","volume":"61","author":"MM Center","year":"2012","unstructured":"Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079\u201392.","journal-title":"Eur Urol"},{"key":"283_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P","volume":"91","author":"L Cheng","year":"2001","unstructured":"Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001;91:66\u201373.","journal-title":"Cancer"},{"key":"283_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.eururo.2008.09.043","volume":"55","author":"A Briganti","year":"2009","unstructured":"Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009;55:261\u201370.","journal-title":"Eur Urol"},{"key":"283_CR4","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","volume":"32","author":"F Abdollah","year":"2014","unstructured":"Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol. 2014;32:3939\u201347.","journal-title":"J Clin Oncol"},{"key":"283_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","volume":"7","author":"EM Messing","year":"2006","unstructured":"Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472\u20139.","journal-title":"Lancet Oncol"},{"key":"283_CR6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.eururo.2017.09.027","volume":"73","author":"KA Touijer","year":"2018","unstructured":"Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, et al. Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies. Eur Urol. 2018;73:890\u20136.","journal-title":"Eur Urol"},{"key":"283_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.21037\/tau.2018.01.06","volume":"7","author":"ZA Siddiqui","year":"2018","unstructured":"Siddiqui ZA, Krauss DJ. Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy. Transl Androl Urol. 2018;7:378\u201389.","journal-title":"Transl Androl Urol"},{"key":"283_CR8","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1002\/cncr.31726","volume":"124","author":"TL Jang","year":"2018","unstructured":"Jang TL, Patel N, Faiena I, Radadia KD, Moore DF, Elsamra SE, et al. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer. 2018;124:4010\u201322.","journal-title":"Cancer"},{"key":"283_CR9","doi-asserted-by":"publisher","unstructured":"De Cicco L. Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: do we have certainties today? Cancer. 2019. https:\/\/doi.org\/10.1002\/cncr.32055.","DOI":"10.1002\/cncr.32055"},{"key":"283_CR10","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.juro.2012.08.028","volume":"188","author":"JK Mullins","year":"2012","unstructured":"Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol. 2012;188:2219\u201324.","journal-title":"J Urol"},{"key":"283_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.eururo.2011.11.053","volume":"61","author":"SA Boorjian","year":"2012","unstructured":"Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol. 2012;61:664\u201375.","journal-title":"Eur Urol"},{"key":"283_CR12","doi-asserted-by":"publisher","unstructured":"Krimphove MJ, Theissen LH, Cole AP, Preisser F, Mandel PC, Chun FKH. Performance and Impact of prostate specific membrane antigen-based diagnostics in the management of men with biochemical recurrence of prostate cancer and its role in salvage lymph node dissection. World J Mens Health. 2019. https:\/\/doi.org\/10.5534\/wjmh.180133.","DOI":"10.5534\/wjmh.180133"},{"key":"283_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618\u201329.","journal-title":"Eur Urol"},{"key":"283_CR14","first-page":"4662","volume":"63","author":"SF Shariat","year":"2003","unstructured":"Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003;63:4662\u201370.","journal-title":"Cancer Res"},{"key":"283_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/1078-0432.CCR-05-2706","volume":"13","author":"H Miyake","year":"2007","unstructured":"Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res. 2007;13:1192\u20137.","journal-title":"Clin Cancer Res"},{"key":"283_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.urolonc.2011.04.003","volume":"31","author":"Y Kusuda","year":"2013","unstructured":"Kusuda Y, Miyake H, Kurahashi T, Fujisawa M. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction. Urol Oncol. 2013;31:615\u201321.","journal-title":"Urol Oncol"},{"key":"283_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.eururo.2013.02.007","volume":"66","author":"MM Heck","year":"2014","unstructured":"Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, et al. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study. Eur Urol. 2014;66:222\u20139.","journal-title":"Eur Urol"},{"key":"283_CR18","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-17-3771","volume":"24","author":"MM Heck","year":"2018","unstructured":"Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, et al. Molecular lymph node status for prognostic stratification of prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection. Clin Cancer Res. 2018;24:2342\u20139.","journal-title":"Clin Cancer Res"},{"key":"283_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research N.","year":"2015","unstructured":"Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011\u201325.","journal-title":"Cell"},{"key":"283_CR20","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.2003.08.142","volume":"21","author":"SF Shariat","year":"2003","unstructured":"Shariat SF, Kattan MW, Erdamar S, Nguyen C, Scardino PT, Spencer DM, et al. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol. 2003;21:1223\u201331.","journal-title":"J Clin Oncol"},{"key":"283_CR21","doi-asserted-by":"publisher","first-page":"576.e1","DOI":"10.1016\/j.urolonc.2019.05.006","volume":"37","author":"A Offermann","year":"2019","unstructured":"Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, et al. TRIM24 as an independent prognostic biomarker for prostate cancer. Urol Oncol. 2019;37:576.e1\u2013e10.","journal-title":"Urol Oncol"},{"key":"283_CR22","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/pros.23202","volume":"76","author":"MM Heck","year":"2016","unstructured":"Heck MM, Thalgott M, Schmid SC, Oh WK, Gong Y, Wang L, et al. A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer. Prostate. 2016;76:1160\u20138.","journal-title":"Prostate"},{"key":"283_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969\u201374.","journal-title":"JAMA"},{"key":"283_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387\u201391.","journal-title":"Br J Cancer"},{"key":"283_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591\u20137.","journal-title":"JAMA"},{"key":"283_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.eururo.2011.02.026","volume":"59","author":"SA Boorjian","year":"2011","unstructured":"Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59:893\u20139.","journal-title":"Eur Urol"},{"key":"283_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387:70\u201382.","journal-title":"Lancet"},{"key":"283_CR28","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1200\/JCO.2005.03.6020","volume":"24","author":"AC Ferrari","year":"2006","unstructured":"Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, et al. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol. 2006;24:3081\u20138.","journal-title":"J Clin Oncol"},{"key":"283_CR29","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1158\/0008-5472.CAN-14-3297","volume":"75","author":"CJ Ko","year":"2015","unstructured":"Ko CJ, Huang CC, Lin HY, Juan CP, Lan SW, Shyu HY, et al. Androgen-induced TMPRSS2 activates matriptase and promotes extracellular matrix degradation, prostate cancer cell invasion, tumor growth, and metastasis. Cancer Res. 2015;75:2949\u201360.","journal-title":"Cancer Res"},{"key":"283_CR30","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.3892\/mmr.2017.7281","volume":"16","author":"Z Wang","year":"2017","unstructured":"Wang Z, Wang Y, Zhang J, Hu Q, Zhi F, Zhang S, et al. Significance of the TMPRSS2: ERG gene fusion in prostate cancer. Mol Med Rep. 2017;16:5450\u20138.","journal-title":"Mol Med Rep"},{"key":"283_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ijc.1526","volume":"94","author":"MH Vaarala","year":"2001","unstructured":"Vaarala MH, Porvari K, Kyllonen A, Lukkarinen O, Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer. 2001;94:705\u201310.","journal-title":"Int J Cancer"},{"key":"283_CR32","doi-asserted-by":"publisher","unstructured":"Uhlen M, Zhang C, Lee S, Sj\u00f6stedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357. https:\/\/doi.org\/10.1126\/science.aan2507.","DOI":"10.1126\/science.aan2507"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-00283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-00283-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-00283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T23:13:36Z","timestamp":1632525216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-00283-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1038\/s41391-020-00283-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}